Barclays maintains Pfizer at Equalweight, PT $40.00

  • Investing.com
Barclays maintains Pfizer at Equalweight, PT $40.00
Credit: © Reuters.

A Barclays analyst maintained Pfizer (NYSE: PFE) at Equalweight and a price target of $40.00 from a prior price target of $43.00.

Prior to this rating, Pfizer had 12 buy ratings, 13 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Pfizer, click here. For more news on Pfizer, click here.

Pfizer's stock price closed at $39.06. They are down -4.5% in the last month and down -21.35% in the last 12 months.

According to Investing Pro, Pfizer's fair value is $52.94, an upside of 35.52%. Pfizer's fair value comes with a low degree of uncertainty, according to InvestingPro.

Check out Pfizer's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100